← FDA DRUG APPROVALS

FDA ANDA · ANDA214008

TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE

Sponsor: NATCO

APPLICATION
ANDA214008
TYPE
ANDA
ORIGINAL APPROVAL
2023-06-13
LATEST ACTION
2023-06-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINEPrescription
TIPIRACIL HYDROCHLORIDE EQ 6.14MG BASE, TRIFLURIDINE 15MG · TABLET · ORAL
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINEPrescription
TIPIRACIL HYDROCHLORIDE EQ 8.19MG BASE, TRIFLURIDINE 20MG · TABLET · ORAL

Approval history

2023-06-13UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →